Terry L. Murdock - Jul 5, 2022 Form 4 Insider Report for G1 Therapeutics, Inc. (GTHX)

Role
Chief Operating Officer
Signature
/s/ James Stillman Hanson, attorney-in-fact
Stock symbol
GTHX
Transactions as of
Jul 5, 2022
Transactions value $
-$3,351
Form type
4
Date filed
7/6/2022, 04:03 PM
Previous filing
Jan 5, 2022
Next filing
Jan 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GTHX Common Stock Sale -$3.35K -648 -3.01% $5.17 20.9K Jul 5, 2022 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the Reporting Person.
F2 The price represents the weighted average price with a low of $5.10 and a high of $5.44. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 Represents (i) 2,032 shares of common stock; (ii) 6,875 RSUs from award granted on January 4, 2021; and (iii) 12,000 RSUs from award granted on January 3, 2022.